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coronary artery spasm (Table 1). However, when adjusted by age, the
statistical signiﬁcance disappeared (OR, 0.965; 95% CI, 0.898-1.037 ;
P-value, 0.335). The incidence of MACE was 11.1% in male gender
and 8.6% in female gender. In male gender, the serum uric acid
level between the groups with and without MACE was similar but in
female gender, the level of uric acid was higher in the group with
MACE, compare to the group without MACE. However, when
adjusted by age, uric acid was not associated with MACE (Table 2).
CONCLUSIONS In our study, uric acid was neither the risk factor nor
prognostic factor for clinical outcomes during 3-year follow-up period
in coronary vasospastic angina regardless of gender.
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BACKGROUND Increased platelet inhibition by prasugrel has been
shown to result in reduced ischemic events along with greater
bleeding hazards in patients with acute coronary syndromes (ACS)
treated with percutaneous coronary intervention (PCI). Yet, there is
limited experience with the use of prasugrel in routine practice. We
evaluated 1-year outcomes with routine prasugrel treatment after ACS
in a large-scale registry.
METHODS The Rijnmond Collective Cardiology Research (CCR) regis-
try is a prospective, observational study with enrollment of 4,259 PCI-
treated ACS patients with 1-year follow-up in the larger region of Rot-
terdam, the Netherlands. Based on implemented hospital protocols, all
patients received prasugrel as ﬁrst-choice antiplatelet agent, unless
contraindicated, including pretreatment before arrival at cathlab either
pre-hospital (ambulance), in referring hospital or in-hospital (emer-
gency room or coronary care unit), whenever possible. All events are
validated by an independent clinical endpoint committee.
RESULTS A total number of 2729 patients (64%) received prasugrel in
the registry after the index event. Half of these patients presented with
ST-elevation myocardial infarction, 77% were men, and mean age was
60.110.8 years. Reasons for not subscribing prasugrel included, for
instance, age >75 years (n¼611 [42% of pts receiving clopidogrel]) and
previous stroke or TIA (n¼270 [18.4%]). At the time of current abstract
submission, 70% of all study events were validated. At 1 year, the pri-
mary endpoint, a composite of all-cause death and myocardial infarc-
tion, occurred in 2.9% of patients receiving prasugrel. All-cause deathoccurred in 2.0%, myocardial infarction in 1.0%, target-vessel revas-
cularization in 2.1%, stent thrombosis in 0.5%, and stroke in 0.3% of the
prasugrel-treated patients. The safety endpoint of all Thrombolysis in
Myocardial Infarction major bleeding episodes, whether related or not
related to coronary-artery bypass grafting was observed in 1.1% of pa-
tients receiving prasugrel. At TCT 2015, the remaining events will be
validated and available for presentation.
CONCLUSIONS Early results from the CCR study show that prasugrel-
treated ACS patients have low rates of ischemic events, including
overall mortality, and no excess rates of major bleeding in routine
practice up to 1 year post-PCI.
CATEGORIES CORONARY: Acute Coronary Syndromes
TCT-183
Repeat Coronary Angiography in Patients with Previously
Normal Coronary Arteries
Vitaliy Androshchuk,1 Majd B. Protty,2 Phillip M. Freeman,3
Richard A. Anderson,1 Tim Kinnaird,4 Nick Ossei-Gerning5
1University Hospital of Wales, Cardiff, Wales; 2University Hospital of
Wales, Cardiff, United Kingdom; 3Cardiff University, Cardiff,
Glamorgan; 4university Hospital of Wales, Cardiff, wales; 5University
Hospital of Wales, Cardiff, South Glamorgan
BACKGROUND Coronary artery disease (CAD) is a serious public and
economic health problem. Coronary angiography is a gold standard for
diagnosing CAD and is indicated in patients with 61-90% pre-test
probability of the disease when the diagnosis cannot be made on
clinical grounds alone and when revascularization is being consid-
ered. Around 25% of coronary angiograms demonstrate normal ar-
teries. The natural history of normal coronary angiogram is poorly
understood. We evaluated the progression of disease in patients with
normal coronary angiography and assessed the overall survival and
event-free survival from acute myocardial infarction in these patients.
METHODS We interrogated the Central Cardiac Audit Database
(CCAD) between November 2005 and December 2013 to identify pa-
tients with normal or ’near-normal’ coronary angiography. De-
mographic, clinical and angiographic data was recorded. This
database was linked with the Patient Episode Database for Wales
(PEDW) and the datasets from the Ofﬁce for National Statistics (for
mortality) using the Secure Anonymized Information Linkage (SAIL)
databank. This allowed for the extraction of information from all the
sources above on the basis of the International Statistical Classiﬁca-
tion of Diseases (ICD-10) using the Structured Query Language (SQL).
RESULTS Out of over 20,000 patients undergoing coronary angiog-
raphy between November 2005 and December 2013, 5032 patients had
normal coronaries and minor CAD. Of 5032 patients, 136 underwent
repeat angiography, with 131(96.3%) and 5(3.7%) patients having two
and three repeat investigations respectively. Mean time between
procedures was 3.3 (1.82) years. Of those 136 patients, at the median
follow up of 6.8 years, no change in disease progression was
demonstrated in 108(79.4%) patients on the follow up studies. In the
remaining 28 (20.6%) patients, normal coronaries progressed to minor
CAD. No patients progressed beyond minor CAD. Patients with normal
coronaries had signiﬁcant better survival than patients with minor
CAD (p<0.05), but survival free from MI was >99.5% in both groups at
the median of 5 years follow up. (p¼0.09)
CONCLUSIONS Normal coronary angiography and minor CAD is un-
likely to progress to signiﬁcant disease at 7 years and the incidence of
MI in these patients is rare at 5 years. Therefore, repeating coronary
angiography within at least 5 years is not indicated.
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